miR-216b suppresses glioma progression by targeting SREBP1-mediated lipid metabolic reprogramming
Lipid metabolic reprogramming contributes to glioma progression. Although miR-216b has tumor-suppressive effects in glioma, its role in lipid metabolism remains unclear. Gain- and loss-of-function assays assessed its effects on proliferation, colony formation, migration and invasion. Biotin-labelled miRNA pull-down, dual-luciferase reporter and AGO-RIP assays validated the interaction between miR-216b and SREBP1. Triglyceride measurement, BODIPY staining, Oil Red O staining and SREBP1 rescue experiments were performed to evaluate lipid accumulation and functional relevance. miR-216b was markedly downregulated in glioma cell, and its overexpression suppressed malignant phenotypes and lipid accumulation. Mechanistically, miR-216b directly targeted SREBP1 and reduced its expression, while SREBP1 restoration partially rescued lipid accumulation and malignant phenotypes suppressed by miR-216b. miR-216b suppresses glioma progression by targeting SREBP1-mediated lipid metabolic reprogramming, highlighting the miR-216b/SREBP1 axis as a potential therapeutic target in glioma.
Authors
- Zirui Xia
- Qing Liu
- Fayou Zhou
- Jun Liu
- Gang Chen
- Hua Chen
Institutions
- Wannan Medical College (CN)
- Dalian Medical University (CN)
- Anhui Medical University (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1186/s12885-026-17182-w
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00